Abstract:Hui Zhang, 1, &ast Jinyi Lin, 2, &ast Yihui Shen, 1 Jianan Pan, 3 Chunhui Wang, 4 Leilei Cheng 1 1 Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai, People's Republic of China; 2 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, People's Republic of China; 3 Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, People's Republic of China; 4 Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Leilei Cheng, Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai, 200032, People's Republic of China, Fax +86-21-51217561, Email Purpose: Immune checkpoint inhibitors (ICIs)-related myocarditis is now one of the most critical immune-related adverse effects (irAEs) in tumor immunotherapy, which has raised great concern in cardio-oncology. The pathogenesis involved in cardiac injury remains elusive. Crocin, the main component of saffron, has shown distinct functions in cardioprotective and anti-inflammation properties. We therefore aimed to investigate the potential effect of crocin on the protection of ICIs-related myocarditis and its underlying molecular mechanism. Methods: We immunized the BALB/c mice with murine cardiac troponin I (cTnI) peptide and additionally gave anti-mouse programmed death 1 (PD-1) to induce the mouse model of ICIs-related myocarditis. Mice were treated with crocin at different dosages. In vitro, HL-1 cells were pre-incubated with crocin at different concentrations and then stimulated with lipopolysaccharide (LPS). Myocardial contractile functions, myocardial inflammation and fibrosis, and myocardial injury were assessed. The expressions of pyroptosis-related proteins and nuclear factor-κB (NF-κB) pathway were evaluated. Results: Crocin treatment could partially reverse the ICIs-related myocarditis in terms of improving heart function, ameliorating inflammation and fibrosis in the myocardium, and alleviating myocardial injury. Mechanistically, ICIs administration significantly activated pyrin domain-containing protein 3 (NLRP3) inflammasome in cardiomyocytes. Crocin treatments significantly downregulated the expression of NLRP3, cleaved gasdermin D (GSDMD), cleaved caspase1, interleukin-1β (IL-1β), and IL-18. Besides, crocin inhibited the activation of NF-κB pathway, which performed as reducing the phosphorylation of p-NF-kappa-B inhibitor-α (p-IκBα), degradation of IκBα, phosphorylation of p65 and p65 DNA binding activity both in vivo and in vitro. Conclusion: By reversing the pyroptosis in cardiomyocytes, crocin treatment in a mouse model exerted great potential to aid in the prevention of ICIs-related myocarditis from a novel target. Graphical Keywords: cardio-oncology, immune checkpoint inhibitors, autoimmune myocarditis, programmed death 1, immune-related adverse effects Graphical In the past decade, the rise and development of immune checkpoint inhibitors (ICIs) have brought great clinical advances in cancer immunotherapy. 1,2 ICIs target different immune checkpoints including the programmed death 1 (PD-1) such as Nivolumab and Pembrolizumab, programmed death ligand 1 (PD-L1) like Atezolizumab, Avelumab, and Durvalumab, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors like Tremelimumab and Ipilimumab. 3 Since immune checkpoints also play a critical role in autoimmune tolerance, the activation of the immune system by ICIs may cause a wide range of autoimmune responses, which is called immune-related adverse effects (irAEs), including colitis, hepatitis, pneumonitis, thyroiditis, myositis, hypophysitis, and dermatitis. 4–6 These irAEs are largely reversible and can typically be controlled with the administration of glucocorticoid therapy. 5–7 However, severe cardiovascular effects, especially myocarditis and fatal heart failure caused by ICIs, have largely been underestimated in the past few years, which has raised great concern in cardio-oncology. 8 In 2018, a multicenter clinical study showed that the incidence of ICIs-related myocarditis was 1.14%. 9 In addition, the onset of ICIs-related myocarditis could be as early as 2 weeks after ICIs initiated, 10 the median ti -Abstract Truncated-

Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization

IgG Immune Complex-Induced Acute Lung Injury is Ameliorated by Camp Via Down-Regulation of C/EBP- and AP-1-mediated Transcriptions.

JAK2 inhibitor protects the septic heart through enhancing mitophagy in cardiomyocytes

Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation

Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway

Baricitinib relieves DSS-induced ulcerative colitis in mice by suppressing the NF-κB and JAK2/STAT3 signalling pathways

Identification of key immune-related genes and potential therapeutic targets in immune checkpoint inhibitor-associated myocarditis

Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF-κB Pathway

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation：a propensity score-matched and retrospective analysis

Inhibition of MyD88 by a Novel Inhibitor Reverses Two-Thirds of the Infarct Area in Myocardial Ischemia and Reperfusion Injury

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis

Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib

Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor-associated myocarditis

Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19

Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use

Pharmacological upregulation of macrophage-derived itaconic acid by pubescenoside C attenuated myocardial ischemia–reperfusion injury

Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Abstract 15045: Anti CTLA-4 and PD-1 Monoclonal Antibodies Increases Systemic SDF-1 and Galectin-3 Levels and Reduces Myocardial Strain Through NLRP3 and MyD-88 Pathways

P1594: BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways